Guide to Using Your Pillcheck

Welcome to your Pillcheck pharmacogenetic test results! They show how your DNA affects your response to many prescription medications. Your results can help determine safer, more effective medications and dosages to fit your unique genetic profile. They can also provide peace of mind that medications you're currently taking are the right ones for you.

There are four parts to your Pillcheck results:

1. **Summary of Your Test** - for you to learn which medications you have a higher risk of side effects or poor response
2. **Information for Specialists** - your genetic profile and test details for healthcare providers
3. **Personalized Results for You** - use it for any medications you may need in the future
4. **Pharmacist Opinion Letter** - your pharmacist action plan with personalized treatment recommendations. Take this to your doctor to discuss (available now as a separate document in your account)

How to use the Summary of Your Test

The colour-coded summary of your Pillcheck shows your predicted risk for all medications included on the test. These are key medical facts about you that your doctor should consider. Use it to check prescriptions you're taking now and for any new medication being considered in the future. The summary shows which medications may be right for you and which ones should be used with extra caution. Click any drug name in the summary to see your detailed test results for it.

You may not recognize the names of the drugs in your report because they are 'generic' drug names. If you check the label of your prescriptions, you should be able to find the generic name and then find it in the report.

Meaning of the symbols in your report

Normal drug metabolism and response. No additional dose adjustment needed.

Altered drug metabolism. Can affect clinical response, may require dose adjustment or increased monitoring.

Substantially altered drug metabolism. Requires physicians to adjust dose or consider alternative medications.

Uncertain activity requires caution in drug use. A rare or indeterminate combination of genetic markers is present.

What to do with your Pillcheck Results

- Bring a copy of your Pharmacist Opinion Letter to your doctor or pharmacist (either print or bring on a mobile device).
- Discuss your Pillcheck results with your doctor to improve efficacy and safety of your treatment plan.
- Since your genetic make-up doesn't change, be sure to consult your Pillcheck Report whenever you are prescribed new medications.
- You can grant your doctor/pharmacist online access to your full Pillcheck report by sending us your provider's name, email, phone, and fax numbers.

You or your provider can contact us at support@pillcheck.ca, 1-877-409-3629, or contact the pharmacist listed on your Pharmacist Opinion Letter if you have any questions about your Pillcheck. More information for healthcare providers can be found at www.pillcheck.ca/providers.

TEST_SAMPLE|2025-03-13 19:40:31|cef4348051149308188f4050d47a8c9|Pillcheck FSQS January 2025|Pillcheck FSQS v.6|db.285|rep.285|det.285

Other Notes

- It's possible that your report will indicate there are no issues with any of the medications you're taking (for example, they're all in the Green category), yet you may still feel you are having issues. There may be other factors involved in how you respond to medications (such as your medical condition, age, liver and kidney function, etc.). Your doctor is the best person to discuss this with.
- Although Pillcheck is a comprehensive pharmacogenetic test, not all medications are listed on the report, even ones you may currently be taking. This is because not all drugs can be assessed by pharmacogenetics or there is not enough clinical information yet to report on certain medications.
- We'll update your report as new information on medications become available. We'll contact you by email to let you know when your report is updated.

DO NOT CHANGE ANY MEDICATIONS OR DOSAGE PRIOR TO CONSULTING YOUR PHYSICIAN OR PHARMACIST, WHO SHOULD DETERMINE AN APPROPRIATE DOSE. Please note, this report is intended for educational purposes only and does not constitute medical advice.

TEST_SAMPLE|2025-03-13 19:40:31|cef4348f05114f93d8188f4050d47a8c9|Pillcheck FSQS January 2025|Pillcheck FSQS v.6|db.285|rep.285|det.285

pillcheck

Summary of Your Test

TREATMENT AREA	CONSIDER ALTERNATIVES	USE WITH CAUTION	STANDARD PRECAUTION
Antibacterial		Isoniazid	Dapsone Nitrofurantoin
Antiemetics (nausea)	Aprepitant Dronabinol Fosaprepitant Meclizine Rolapitant	Dolasetron Ondansetron Palonosetron Tropisetron	
Antifungal	Isavuconazonium Itraconazole Posaconazole	Terbinafine	Voriconazole
Antimalarial			Primaquine Tafenoquine
Antiviral	Fosamprenavir	Darunavir Maraviroc Nirmatrelvir / ritonavir	Atazanavir Dolutegravir Efavirenz Nevirapine Raltegravir Remdesivir

Information for Specialists

Customer Genetic Profile

Biomarker	Value	Biomarker	Value
ABCG2	WT/c.421C>A	DPYD	*1/*1
ADRB2	G/G	F2	A/A
CYP1A2	*1A/*1A	F5	C/C
CYP2B6	*1/*1	G6PD	WT/WT
CYP2C19	*1/*1	NAT2	*4/*5A
CYP2C8	*1A/*1A	NUDT15	*1/*1
CYP2C9	*3/*3	OPRM1	A/A
CYP2D6 CYP2D6 CNV	*1/*1 3N	SLCO1B1	*5/*5
CYP3A4	*6/*6	TPMT	*1/*2
CYP3A5	*1/*3	UGT1A1	*1/*1
CYP4F2	C/C	UGT2B15	A/C
		VKORC1	T/T

TEST_SAMPLE|2025-03-13 19:40:31|cef4348f051f493d8188f4050d47a9c9|Pillcheck FSQS January 2025|Pillcheck FSQS v.6|db.285|rep.285|det.285

Technology used in the testing process

Gene	Alleles Tested
ABCG2	c.421C>A, c.376C>T
ADRB2	rs1042713 G/A
CYP1A2	*1E, *1F, *1J, *1K, *6, *7, *8, *15
CYP2B6	*2, *5, *6, *7, *8, *13, *18, *22, *34
CYP2C19	*2, *3, *4, *6, *8, *9, *10, *17
CYP2C8	*2, *3, *4
CYP2C9	*2, *3, *5, *6, *8, *9, *11, *12, *27
CYP2D6	*3, *4, *5, *6, *7, *9, *10, *12, *17, *29, *41, *64, *69, *82, *109
CYP3A4	*3, *6, *11, *12, *16, *17, *18, *19, *22
CYP3A5	*2, *3, *6, *7
CYP4F2	rs2108622 C/T
DPYD	*2A, *4, *5, *6, *7, *8, *9A, *9B, *10, *11, *13, c.2846A>T, HapB3, c.557A>G, c.61C>T
F2	rs1799963 G/A
F5	rs6025 C/T
G6PD	Mediterranean
NAT2	*5A, *5B, *5E, *5P, *6A, *6C, *7C
NUDT15	*2, *5
OPRM1	rs1799971 A/G
SLCO1B1	*1B, *5, *9, *15, *31
TPMT	*2, *3A, *8
UGT1A1	*6, *27, *80
UGT2B15	rs1902023 A/C
VKORC1	rs9923231 C/T

Technology: Genotyping was performed using the Applied Biosystems™ QuantStudio™ platform and this report is powered by Pillcheck technology.

Limitations: This test will not detect all known mutations that result in altered gene activity. *1 or wild-type alleles are reported by default if those listed were not detected. IND values are conservatively assigned to alleles that could not be determined with complete certainty. Only listed mutations are tested for and absence of a detected mutation does not rule out the possibility of sensitivity to a specific drug due to the presence of other mutations or other environmental factors.

Additional genetic testing by sequencing might uncover other functional variations that the individual may carry that also affect the medication response, but were not detected in this analysis.

TEST_SAMPLE|2025-03-13 19:40:31|cef4348f05114f93d8188f4050d47a8c9|Pillcheck FSQS January 2025|Pillcheck FSQS v.6|db.285|rep.285|det.285

Drug Page Index

Personalized Results for You

Abrocitinib

General drug info:
https://portal.pillcheck.net/medication/R3Y4

Normal abrocitinib clearance is anticipated. Follow standard starting dose recommendations. Abrocitinib is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment. Avoid use of stong or moderate inhibitors of CYP2C19 and/or CYP2C9. When co-administration of strong CYP2C19 inhibitor is required, reduce the starting dose to 50mg once daily. If an adequate response is not achieved with 50 mg orally daily after 12 weeks, consider increasing daily dosage to 100 mg. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg. EMA and Health Canada drug labels do not require dose adjustment.

Biomarker	Value	Interpretation	Level of evidence
CYP2C19	*1/*1	Normal metabolizer	FDA

TEST_SAMPLE|2025-03-13 19:40:31|cef43480511493d8188f4050d47a8c9|Pillcheck FSQS January 2025|Pillcheck FSQS v.6|db.285|rep.285|det.285

Acenocoumarol

General drug info:
https://portal.pillcheck.net/medication/E4C8

Use 50% of the standard initial dose and more frequent monitoring of the INR. Consider alternative treatment with Factor Xa inhibitors.

Biomarker	Value	Interpretation	Level of evidence
CYP2C9	*3/*3	Poor metabolizer	CPIC B
VKORC1	T/T	Low Vitamin K production	CPIC B

Adagrasib

General drug info:
https://portal.pillcheck.net/medication/X7E9

Significantly reduced adagrasib clearance is anticipated. Be altered to increase the risk of QT prolongation, gastrointestinal and other side effects. Avoid concomitant use of adagrasib with other products with a known potential to prolong the QTc interval. Avoid the use of CYP3A4 inhibitors.

Biomarker	Value	Interpretation	Level of evidence
CYP3A4	*6/*6	Poor metabolizer	FDA

Agomelatine

General drug info:
https://portal.pillcheck.net/medication/K7V4

Be alert about potentially reduced agomelatine exposure and reduced clinical response in smoking patients. Other environmental factors can affect agomelatine concentrations. Avoid concomitant use of potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin).

Biomarker	Value	Interpretation	Level of evidence
CYP1A2	*1A/*1A	Normal metabolizer	EMA
CYP2C9	*3/*3	Poor metabolizer	EMA

Alfuzosin

General drug info:
https://portal.pillcheck.net/medication/F8M7

Be aware of significantly reduced CYP3A4 function and alfuzosin clearance rates. Consider dose reduction or alternative treatment options due to the significantly increased risk of hypotension and syncope.

Biomarker	Value	Interpretation	Level of evidence
CYP3A4	*6/*6	Poor metabolizer	FDA

Alirocumab

General drug info:
https://portal.pillcheck.net/medication/Y6X4

The variation you carry in the SLCO1B1 gene indicates that you have a high myopathy risk and will be statin-intolerant. Consider treatment with PCSK9 inhibitors.

Biomarker	Value	Interpretation	Level of evidence
SLCO1B1	*5/*5	Poor function	FDA